Burton Christopher M, Carlsen Jørn, Mortensen Jann, Andersen Claus B, Milman Nils, Iversen Martin
Department of Cardiology, Division of Lung Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
J Heart Lung Transplant. 2007 Jul;26(7):681-6. doi: 10.1016/j.healun.2007.04.004.
The objectives of this study were to describe the natural history of bronchiolitis obliterans syndrome (BOS) in a large consecutive series of patients from a national center in accordance with the most recent grading criteria, and to examine the prognosis with respect to onset and severity of BOS.
All patients receiving a cadaveric lung transplant between 1992 and 2004 were included in the study (n = 389). Exclusion criteria were patients not surviving at least 3 months after transplantation (n = 39) and lack of available lung function measurements (n = 4).
The 1-, 3-, 5- and 10-year actuarial survival rates for the entire series were 81%, 67%, 60% and 36%, respectively. The 1-, 3-, 5- and 10-year actuarial freedom from BOS Grade > or = 1 was 81%, 53%, 38% and 15%, respectively. A Cox regression model with BOS grade as a time-dependent covariate was performed in a sub-group of patients surviving at least 3 years (n = 237). Both progression from BOS Grade 1 to 2 and from BOS Grade 2 to 3 were associated with a significant increase in mortality: hazard ratio (HR) = 3.1 (confidence interval [CI] 1.2 to 7.9) and HR = 2.9 (CI 1.6 to 5.3), respectively. The addition of a non-time-dependent covariate to signify early (within 18 months of transplantation) or late (after 18 months) development of BOS was not significant (p = 0.5).
The development and progression of chronic allograft rejection after lung transplantation (BOS Grades 2 and 3) is associated with a 3-fold increase in the risk of death at each stage, irrespective of whether BOS developed early or late.
本研究的目的是根据最新的分级标准,描述来自一个国家级中心的大量连续系列患者闭塞性细支气管炎综合征(BOS)的自然病史,并研究BOS的发病和严重程度的预后情况。
纳入1992年至2004年间接受尸体肺移植的所有患者(n = 389)。排除标准为移植后存活时间不足3个月的患者(n = 39)以及缺乏可用肺功能测量数据的患者(n = 4)。
整个系列的1年、3年、5年和10年实际生存率分别为81%、67%、60%和36%。1年、3年、5年和10年无BOS≥1级的实际生存率分别为81%、53%、38%和15%。在至少存活3年的患者亚组(n = 237)中,进行了以BOS分级作为时间依赖性协变量的Cox回归模型分析。从BOS 1级进展到2级以及从BOS 2级进展到3级均与死亡率显著增加相关:风险比(HR)分别为3.1(置信区间[CI] 1.2至7.9)和HR = 2.9(CI 1.6至5.3)。添加一个非时间依赖性协变量以表示BOS的早期(移植后18个月内)或晚期(18个月后)发生并不显著(p = 0.5)。
肺移植后慢性移植物排斥反应(BOS 2级和3级)的发生和进展与每个阶段死亡风险增加3倍相关,无论BOS是早期还是晚期发生。